Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs Royal Medical Center

Invyncible
Graded #303

Higher grade

vs+11.600000000000001
Royal Medical Center
Graded #492

Lower grade

The verdict

Invyncible takes it — 61/100 to 49.4/100.

Invyncible grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Invyncible is a Florida-based telehealth platform offering semaglutide and tirzepatide programs for weight management.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueInvyncible +33
55
22
Dose & formulationInvyncible +22
64
42
Clinical oversightInvyncible +8
70
62
Labs & monitoringRoyal Medical Center +34
52
86
FulfillmentInvyncible +17
65
48
Contract termsInvyncible +6
61
55
Invyncible · left barRoyal Medical Center · right bar

The numbers

MetricInvyncibleRoyal Medical Center
WeighScore61/10049.4/100
GradeCC
Scorecard rank#303#492
Semaglutide$192/mo (0.5 mg dose, compounded)Not disclosed
Tirzepatide$210/mo (compounded)$450/mo (2.5 mg dose, compounded)
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Invyncible

Graded #303 · C

Strengths

  • Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
  • Physical corporate address published (St. Petersburg, FL)
  • LegitScript verification seal displayed
  • No long-term commitment required
  • Offers both semaglutide and tirzepatide programs

Where it loses points

  • Pricing not disclosed on the public site — fully gated behind signup
  • Drug forms (compounded vs brand, injection vs oral) not disclosed
  • 503A vs 503B designation not specified
  • Pharmacy partner not named
  • States served not listed publicly
Royal Medical Center

Graded #492 · C

Strengths

  • Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
  • Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
  • All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
  • Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
  • Florida physician with 30+ years of practice — a strong physician-led care signal

Where it loses points

  • Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
  • Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
  • No LegitScript badge displayed
  • States served not enumerated — site says 'nationwide' with no state list
  • Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard